| Name | Title | Contact Details |
|---|
The Integrated Health and Social Services University Network for West-Central Montreal (CIUSSS West-Central Montreal) is one of the largest health and social services network in the Montreal area, regrouping over 20 establishments in the west end of Montreal and serving a population of nearly 345,000. We are making the difference, one person at a time. CIUSSS West-Central Montreal`s services and programs span the continuum of healthcare, from hospital to community integrated services to residential care. Our 9,000 employees, including 900 doctors, are guided by values of compassion, integrity and commitment to the quality of care. We are proud of our official bilingual status and the culturally rich identities of our sites. On top of clinical activities, research and teaching play an integral part in the CIUSSS West-Central Montreal network.
Mercury Medical is a Clearwater, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
WelbeHealth is a company that provides full service healthcare and personalized support to help seniors age well at home and in their community.
Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries and chronic conditions. Humacyte`s initial opportunity, a portfolio of human acellular vessels (HAVs), is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte`s 6mm HAVs for AV access for performing hemodialysis was the first product candidate to receive the FDA`s Regenerative Medicine Advanced Therapy (RMAT) expedited review designation, and the HAV technology received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense.